• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Immutep Limited

    2/27/25 6:03:28 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMMP alert in real time by email
    6-K 1 d841699d6k.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 6-K

     

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    Date as February 26, 2025

    Commission File Number 001-35428

     

     

    IMMUTEP LIMITED

    (Exact Name as Specified in its Charter)

     

     

    N/A

    (Translation of Registrant’s Name)

    Level 32, Australia Square

    264 George Street, Sydney

    NSW 2000, Australia

    (Address of principal executive office)

     

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒   Form 40-F ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

    Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

    Yes ☐   No ☒

    If “Yes” is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

     

     

     


    EXHIBIT INDEX

     

    Exhibit

     

    Description of Exhibit

    99.1

     

    Appendix 4D – Half-Year Financial Report


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

    Date: February 26, 2025

     

    IMMUTEP LIMITED
    By:  

    /s/ Marc Voigt

    Name:   Marc Voigt
    Title:   Chief Executive Officer
    Get the next $IMMP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMMP

    DatePrice TargetRatingAnalyst
    5/17/2024$10.00Overweight
    CapitalOne
    8/3/2023$7.00Outperform
    Robert W. Baird
    8/3/2021$8.30Buy
    Ladenburg Thalmann
    7/16/2021$8.00Buy
    Maxim Group
    More analyst ratings

    $IMMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CapitalOne initiated coverage on Immutep with a new price target

      CapitalOne initiated coverage of Immutep with a rating of Overweight and set a new price target of $10.00

      5/17/24 7:43:01 AM ET
      $IMMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Immutep with a new price target

      Robert W. Baird initiated coverage of Immutep with a rating of Outperform and set a new price target of $7.00

      8/3/23 6:20:48 AM ET
      $IMMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann initiated coverage on Immutep with a new price target

      Ladenburg Thalmann initiated coverage of Immutep with a rating of Buy and set a new price target of $8.30

      8/3/21 8:13:45 AM ET
      $IMMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMMP
    SEC Filings

    See more
    • SEC Form 6-K filed by Immutep Limited

      6-K - IMMUTEP Ltd (0001506184) (Filer)

      5/15/25 8:01:16 PM ET
      $IMMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Immutep Limited

      6-K - IMMUTEP Ltd (0001506184) (Filer)

      5/5/25 8:29:10 PM ET
      $IMMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Immutep Limited

      6-K - IMMUTEP Ltd (0001506184) (Filer)

      4/29/25 7:50:42 PM ET
      $IMMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMMP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

      Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcomaDetailed results are planned for presentation at a future medical meeting  SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS) has met its primary endpoi

      5/27/25 8:00:00 AM ET
      $IMMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immutep's Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer

      Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L NSCLC)Notably, ~92% of all evaluable patients have PD-L1 TPS <50%, including 43% with PD-L1 below 1 (TPS <1%), who represent an area of high unmet needData demonstrates significant improvement in response rates compared to historical controls, and safety continues to be favourableMulti-centre INSIGHT-003 is evaluating the same immunotherapy/chemotherapy combination used in the pivotal TACTI-004 Phase III in 1L NSCLCAdditional data from INSIGHT-003 is planned for presentation at a medical conference later this year SYDNEY, AUSTRALIA, May 15, 2025 (GLOBE NEWSWIRE) --  

      5/15/25 8:00:00 AM ET
      $IMMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Immutep's Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

      Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1Mature overall survival data builds on encouraging high response rates with multiple complete responsesPatients with CPS <1 represent a high unmet medical need and have no available treatment options without chemotherapyMeeting with FDA has now been requested to discuss next steps including potential paths to approval SYDNEY, AUSTRALIA, May 05, 2025 (GLOBE NEWSWIRE) --  Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an exc

      5/5/25 8:00:00 AM ET
      $IMMP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Immutep Limited (Amendment)

      SC 13G/A - IMMUTEP Ltd (0001506184) (Subject)

      2/9/24 7:59:50 AM ET
      $IMMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Immutep Limited (Amendment)

      SC 13G/A - IMMUTEP Ltd (0001506184) (Subject)

      2/9/23 7:57:21 AM ET
      $IMMP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Immutep Limited

      SC 13G - IMMUTEP Ltd (0001506184) (Subject)

      2/9/22 8:58:14 AM ET
      $IMMP
      Biotechnology: Pharmaceutical Preparations
      Health Care